Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination "hongqu + gypenosides" (often abbreviated as HG) is a traditional Chinese medicine (TCM) preparation comprising Fermentum Rubrum (hongqu, also known as red yeast rice) and total saponins (gypenosides) extracted from Gynostemma pentaphyllum (Jiaogulan) in a defined weight ratio. Both ingredients are used in TCM for their lipid-lowering, anti-inflammatory, antioxidant, hepatoprotective, and anti-atherosclerotic properties. The combination targets hyperlipidemia, atherosclerosis, and related metabolic or cardiovascular diseases. Mechanistically, HG modulates lipid metabolism genes, improves oxidative and inflammatory profiles, and supports hepatic function, with effects reportedly superior to either ingredient alone or to simvastatin in preclinical models[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hongqu + gypenosides.